Literature DB >> 9790892

The expression, refolding, and purification of the catalytic domain of human collagenase-3 (MMP-13).

N Pathak1, S I Hu, J A Koehn.   

Abstract

We have cloned, expressed, and purified a recombinant C-terminal truncated form (residues Glu103-Asn274) of human collagenase-3 (MMP-13) in Escherichia coli. The molecule contains the catalytic domain of the enzyme and is expressed almost exclusively as inclusion bodies. Using a combination of rapid dilution and diafiltration, the enzyme has been successfully refolded from these inclusion bodies. The protein was purified to homogeneity using cation-exchange and size-exclusion chromatography. The purified enzyme is a monomer with a Mr of approximately 19,600 and was characterized using a variety of techniques including, SDS-PAGE, RP-HPLC, LC-MS, amino acid analysis, and dynamic light scattering. Microheterogeneity at the NH2-terminus of the refolded, purified protein disappeared after incubating for 30-60 min at 37 degreesC. The enzyme was highly active using a fluorescent peptide substrate and was found to release S-GAG from bovine nasal cartilage chips. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790892     DOI: 10.1006/prep.1998.0972

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.

Authors:  Dorothea Piecha; Jürgen Weik; Heike Kheil; Gabriele Becher; Andreas Timmermann; Andreas Jaworski; Maren Burger; Michael W Hofmann
Journal:  Inflamm Res       Date:  2009-11-10       Impact factor: 4.575

2.  1H, 13C and 15N backbone resonance assignments of matrilysin (MMP7) complexed with a sulfonamide hydroxamate-type inhibitor.

Authors:  Li Ou; Qi Zhang; Jingbiao Ma; Wengen Wu; Zhonghua Wang; Fang Zhang; Dawei Ma; Houming Wu
Journal:  J Biomol NMR       Date:  2004-08       Impact factor: 2.835

3.  A single step purification for autolytic zinc proteinases.

Authors:  Erin M Wilfong; Ursala Locklear; Eric J Toone
Journal:  Bioorg Med Chem Lett       Date:  2009-11-05       Impact factor: 2.823

4.  SUMO fusions and SUMO-specific protease for efficient expression and purification of proteins.

Authors:  Michael P Malakhov; Michael R Mattern; Oxana A Malakhova; Mark Drinker; Stephen D Weeks; Tauseef R Butt
Journal:  J Struct Funct Genomics       Date:  2004

Review 5.  Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery.

Authors:  Aaron Dolor; Francis C Szoka
Journal:  Mol Pharm       Date:  2018-05-16       Impact factor: 4.939

6.  Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO.

Authors:  Jeffrey G Marblestone; Suzanne C Edavettal; Yiting Lim; Peter Lim; Xun Zuo; Tauseef R Butt
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

7.  Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.

Authors:  Timothy P Spicer; Jianwen Jiang; Alexander B Taylor; Jun Yong Choi; P John Hart; William R Roush; Gregg B Fields; Peter S Hodder; Dmitriy Minond
Journal:  J Med Chem       Date:  2014-11-11       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.